Ausgabe 4/2018
Inhalt (9 Artikel)
Open Access
Systemic Therapies (M Liu and T Haddad, Section Editors)
Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer
Arielle Heeke, Maria Raquel Nunes, Filipa Lynce
Systemic Therapies (M Liu and T Haddad, Section Editors)
Use of Multigene Prognostic Indices to Guide Clinical Decision-Making Regarding Adjuvant Systemic Therapy
Karthik V. Giridhar, Minetta C. Liu
Systemic Therapies (M Liu and T Haddad, Section Editors)
Optimizing HER2-Directed Therapy in Early-Stage Breast Cancer
Evanthia T. Roussos Torres, Roisin M. Connolly
Systemic Therapies (M Liu and T Haddad, Section Editors)
Novel Agents for the Management of Endocrine Resistant Breast Cancer
Sonya Reid-Lawrence, Ingrid A. Mayer
Clinical Trials (PF Peddi, Section Editor)
Updates on Targeted Therapy for Triple-Negative Breast Cancer (TNBC)
Zorawar S. Noor, Aashini Master
Clinical Trials (PF Peddi, Section Editor)
Updates on Molecular Classification of Triple Negative Breast Cancer
Nkiruka Ezenwajiaku, Cynthia X. Ma, Foluso O. Ademuyiwa
Clinical Trials (PF Peddi, Section Editor)
Adjuvant HER2-Targeted Therapy Update in Breast Cancer: Escalation and De-escalation of Therapy in 2018
Rashmi K. Murthy, Mariana Chavez-MacGregor, Gabriel N. Hortobagyi
Global Breast Cancer (BO Anderson and C Duggan, Section Editors)
Phased Implementation as a Strategy for Stepwise, Sustainable Improvement in Breast Healthcare in Low-Resource Settings
Catherine Duggan, Benjamin O. Anderson
Risk and Prevention (ME Wood, Section Editor)
Non-hormonal Chemoprevention
Naomi Hodde, Marie E. Wood